middle.news
How AdAlta and SHcell Are Revolutionising CAR-T Therapy for Solid Tumours Globally
9:28am on Friday 2nd of January, 2026 AEDT
•
Biotechnology
Read Story
How AdAlta and SHcell Are Revolutionising CAR-T Therapy for Solid Tumours Globally
9:28am on Friday 2nd of January, 2026 AEDT
Key Points
AdAlta’s AdCella to co-develop SHcell’s BZDS1901 CAR-T therapy outside greater China
BZDS1901 targets mesothelin with PD1 armoring, showing strong responses in advanced mesothelioma
AdCella to finance development, establish manufacturing in Australia, and run Phase 1 trials
Novel capital-efficient collaboration model shares commercialization proceeds
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
AdAlta (ASX:1AD)
OPEN ARTICLE